Zafgen up 6% after weight loss drug has positive late-stage trial results – MarketWatch

Zafgen up 6% after weight loss drug has positive late-stage trial results
MarketWatch
Zafgen Inc. ZFGN, +0.40% shares rose 6.4% Monday morning after the company presented positive late-stage data for its drug intended to treat obese patients with type 2 diabetes. The company presented data over the weekend showing the drug, beloranib, …

Share and Enjoy:
  • Print
  • Digg
  • StumbleUpon
  • del.icio.us
  • Facebook
  • Yahoo! Buzz
  • Twitter
  • Google Bookmarks

Comments are closed.